Phase 2a study assesses ammonia-lowering effects in cirrhosis, suggesting further exploration.
In this Phase 2a study, oral YAQ007 demonstrated short-term ammonia-lowering activity at doses ≥4 g BID. Given the exploratory design, these findings are hypothesis-generating and support further clinical evaluation.
No takes yet. Share an insight, caveat, or question.
Ballester et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: